The upper gastrointestinal safety of rofecoxib vs. NSAIDs: An updated combined analysis

Current Medical Research and Opinion

Volumn 20, Issue 10, 2004, Pages 1539-1548

  Watson, Douglas J ^a   Yu, Qinfen ^b   Bolognese, James A ^b   Reicin, Alise S ^b   Simon, Thomas J ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

COX 2 inhibitors; Gastroduodenal ulcers; Gastrointestinal adverse effects; Gastrointestinal bleeding; Nonsteroidal anti inflammatory drugs (NSAIDs)

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OSTEOARTHRITIS; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK REDUCTION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; INTESTINAL PERFORATION; LACTONES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; STOMACH ULCER; SULFONES;

EID: 7644238150     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X3078     Document Type: Conference Paper

References (35)

1. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095-101
2. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992;89:7384-8
3. Holtzman MJ, Turk J, Shornick LP. Identification of a pharmacologically distinct prostaglandin H synthetase in cultured epithelial cells. J Biol Chem 1992;267:21438-45
4. Sirois J, Simmons DL, Richards JS. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthetase in rat preovulatory follicles. Induction in vivo and in vitro. J Biol Chem 1992;267:11586-92
5. Fossilen E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998;28:67-81
6. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-7
7. Cryer B. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger and Fordtran's gastrointestinal and liver disease, 6th ed. Philadelphia: Saunders; 1998. p.343-57
8. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharm Ther 1999;65:336-47
9. Brideau C, Kargman S, Liu S, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996;45:68-74
10. Depre M, Ehrich E, Van Hecken A, et al. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000;56:167-74
11. Sigthorsson G, Crane R, Simon T, et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000;47:527-32
12. Hunt RH, Bowen B, Mortensen ER, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000;109:201-6
13. Lanza FL, Rack MF, Simon TJ, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999;13:761-7
14. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370-7
15. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. J Am Med Assoc 1999:282(20):1929-33
16. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000;343:1520-8
17. Ehrich EW, Schnitzer TJ, Mcllwain H, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999;26:2438-47
18. Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 2000;9:1124-34
19. Cannon GW, Krupa D, Sperling R, Truitt K. Two-year efficacy of rofecoxib and diclofenac in treatment of knee and hip osteoarthritis (OA). Ann Rheum Dis 2002;61(Suppl 1):10
20. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs. ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7
21. Truitt KE, Sperling RS, Ettinger Jr WH, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging 2001;13:112-21
22. Schnitzer TJ, Truitt K, Fleischmann R, et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther 1999;21:1688-702
23. Truitt K, Schnitzer T, Fleischmann R, Seidenberg B, Ehrich E. A two-part placebo and active comparator-controlled study of rofecoxib in the treatment of rheumatoid arthritis (RA): one-year experience. Ann Rheum Dis 2000;59(Suppl 1):165
24. Murphy MG, Kivitz AJ, Palmer M, Zeng Q, Bolognese J, Gertz BJ. The effects of rofecoxib, a cyclooxygenase (COX)-2 specific inhibitor, vs. ibuprofen on biochemical indices of bone turnover in patients with osteoarthritis. J Bone Miner Res 1999;14 (Suppl 1):S342
25. Geba GP, Polis AB, Dixon ME, et al. Rofecoxib results in superior clinical response compared to nabumetone in the treatment of osteoarthritis. Arthritis Rheum 1999;42(Suppl 9):S144
26. Geba GP, Polis AB, Najarian DK, Dixon ME, Storms WW, Weaver AL. Onset of efficacy and patient assessment of clinical response in osteoarthritis (OA): comparison of rofecoxib to nabumetone. J Am Geriatr Soc 2001;49:S126
27. van Adelsburg J, Truitt KE, DeTora LM, et al. One-year results from an active comparator-controlled trial of rofecoxib in patients with rheumatoid arthritis (RA). Arthritis Rheum 2002;46(Suppl 9):S336-S337
28. Geusens PP, Truitt K, Sfikakis P, et al. A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis. Scan J Rheum 2002;31:230-8
29. Hawkey C, Laine L, Quan H, Simon T, Evans JK. Incidence of ulcers with rofecoxib versus naproxen: a double-blind, placebo-controlled endoscopy study in patients with rheumatoid arthritis. Arthritis Rheum 2002;46(Suppl 9):S520
30. Geba GP, Lisse JR, Perlman M, et al. Gastrointestinal tolerability in primary care patients treated with naproxen or rofecoxib for osteoarthritis (OA): the Advantage Trial. Ann Rheum Dis 2001;60(Suppl 1):238
31. Myllykangas-Luosujärvi R, Lu HS, Chen SL, et al. Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration. Scand J Rheumatol 2002;31:337-44
32. Laurenzi M, Vandormael K, Daniels B, et al. Comparison of the tolerability profile of rofecoxib and arthrotec in patients with osteoarthritis - study design and baseline characteristics. Ann Rheum Dis 2000;59(Suppl 1):134
33. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000;43:978-87
34. Silverstein FE, Faich G, Goldstein JL, Simon LS, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. J Am Med Assoc 2000;284:1247-55
35. Goldkind L. Gastrointestinal review. Highlights of the CLASS study, http://www.fda.gov/ohrms/dockets/ac/cder01.htm # Arthritis. Accessed January 23, 2004